Anavex Life Sciences Advances Parkinson’s Disease Treatment with Promising Trial Results

NEW YORK, March 30, 2023** — Anavex Life Sciences has announced promising results from a 48-week Phase 2 extension study
evaluating its lead drug candidate, ANAVEX®2-73 (blarcamesine), in patients
with Parkinson’s disease dementia. The clinical-stage biopharmaceutical company
reports that the study successfully met its primary and secondary objectives,
showing significant improvements in clinical symptoms over the trial period. 

The study assessed the safety, tolerability, and efficacy of ANAVEX®2-73, a small-molecule
activator of the sigma-1 receptor, which is crucial for promoting
neuroplasticity and restoring neural cell homeostasis. According to Anavex Life
Sciences, patients on ANAVEX®2-73 displayed better performance across all
efficacy endpoints, including the Movement Disorder Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) and the Clinical Global Impression – Improvement (CGI-I). 

Dr. Christopher U Missling, President & CEO of Anavex, highlighted the positive outcomes: “It is encouraging that the patients’
clinical symptoms consistently improved longitudinally over time during the
extension phase under active ANAVEX®2-73 treatment.” This promising data
suggests that ANAVEX®2-73 has the potential to slow and possibly reverse the
debilitating symptoms of Parkinson’s disease. 

The Open Label Extension (OLE) study followed a previous double-blind placebo-controlled Phase
2 study, where ANAVEX®2-73 had already demonstrated significant improvements in
MDS-UPDRS Total scores. Despite delays due to the COVID-19 pandemic, the extension
study provided valuable insights into the long-term benefits of the treatment. 

Anavex Life Sciences is now planning a pivotal trial for ANAVEX®2-73,
aiming to further substantiate these initial findings. With Parkinson’s disease
affecting millions worldwide, these advancements represent a significant step
forward in addressing an urgent unmet medical need. 

For more detailed information about Anavex and its ongoing clinical trials, you can visit their
website or follow them on their social media platforms. Refer to this article for related information. 

Learn more about Anavex on https://www.cnbc.com/quotes/AVXL